PTC Therapeutics (NASDAQ:PTCT) Hits New 52-Week Low After Insider Selling

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s stock price reached a new 52-week low on Thursday after an insider sold shares in the company. The company traded as low as $58.37 and last traded at $58.2550, with a volume of 547,250 shares changing hands. The stock had previously closed at $60.23.

Specifically, VP Mark Boulding sold 2,812 shares of the firm’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $61.88, for a total value of $174,006.56. Following the sale, the vice president directly owned 105,272 shares of the company’s stock, valued at approximately $6,514,231.36. This trade represents a 2.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Ratings Changes

Several research firms have issued reports on PTCT. Raymond James Financial set a $106.00 price objective on PTC Therapeutics in a research note on Tuesday, October 20th. UBS Group began coverage on PTC Therapeutics in a research report on Thursday, October 15th. They set a “buy” rating and a $90.00 target price for the company. Morgan Stanley raised their target price on shares of PTC Therapeutics from $93.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Wells Fargo & Company lifted their target price on PTC Therapeutics from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Barclays raised their price target on shares of PTC Therapeutics from $120.00 to $122.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $99.23.

View Our Latest Stock Report on PTCT

PTC Therapeutics Price Performance

The company has a market cap of $4.87 billion, a price-to-earnings ratio of -41.61, a P/E/G ratio of 4.43 and a beta of 0.52. The firm has a 50-day moving average price of $63.64 and a 200 day moving average price of $70.04.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The business had revenue of $357.81 million during the quarter, compared to analysts’ expectations of $306.43 million. PTC Therapeutics’s quarterly revenue was up 69.6% on a year-over-year basis. During the same quarter last year, the company posted $0.20 earnings per share. On average, equities analysts anticipate that PTC Therapeutics, Inc. will post 0.49 EPS for the current fiscal year.

PTC Therapeutics announced that its board has authorized a share repurchase plan on Tuesday, November 3rd that authorizes the company to repurchase $500 million in shares. This buyback authorization authorizes the biopharmaceutical company to buy up to 9.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On PTC Therapeutics

Large investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of PTC Therapeutics during the 2nd quarter worth approximately $1,139,089,000. Jupiter Topco LLC bought a new position in shares of PTC Therapeutics in the second quarter worth about $590,182,000. Janus Henderson Group PLC boosted its stake in shares of PTC Therapeutics by 48.3% in the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock valued at $489,997,000 after purchasing an additional 2,342,101 shares in the last quarter. William Blair Investment Management LLC bought a new position in PTC Therapeutics in the 2nd quarter valued at approximately $140,520,000. Finally, Bank of America Corp DE bought a new stake in shares of PTC Therapeutics during the second quarter worth $118,462,000.

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

Further Reading

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.